Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
Clinical trial NCT04884282 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04884282
- Sponsor
- Fondazione Ricerca Traslazionale
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-12
- Primary completion
- 2027-09-30
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.